Australia's most trusted
source of pharma news
Posted 20 February 2025 AM
The Generic and Biosimilar Medicines Association has thrown its weight behind a triplet of initiatives to boost biosimilar uptake by providing solid incentives for customers and healthcare providers to choose them over originator brands.
In its 2025-26 pre-budget submission, the GBMA promoted reducing the cost to consumers of using biosimilars compared to originator brands, and focused on the needs of patients with complex conditions such as Rheumatoid Arthritis, Crohn's Disease, Multiple Sclerosis, and cancer.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.